- Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first-line treatment of advanced G/GEJ cancer - updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort CShen, L.; Liu, D.; Li, N.; Guo, W.; Liu, T.; Li, H.; Li, J.; Zhao, F.; Sun, M.; Bai, Y.; Deng, Y.; Zhuang, Z.; Fan, Q.; Han, L.; Xia, S.; Zhu, X.; Qi, C.; Xu, L.; Qian, X.; Germa, C.
- First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumorsWang, Yakun; Gong, Jifang; Lin, Rongbo; Zhao, Shen; Wang, Jufeng; Wang, Qianli; Zhang, Yanqiao; Su, Dan; Zhang, Jingdong; Dong, Qian; Lin, Ling; Tian, Wen; Chen, Ying; Yang, Yang; Zhang, Xueyuan; Wan, Xuechao; Gao, Jinfeng; An, Na; Jansen, Valerie Malyvanh; Shen, LinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer.Xu, Rui-Hua; Ruan, Dan-Yun; Zhang, Dong-Sheng; Liu, Fu-Rong; Luo, Su-Xia; Zhuang, Zhi-Xiang; Wang, Zhen-Ning; Liu, Fu-Nan; Zhang, Yan-Qiao; Yang, Jian-Wei; Chen, Zhen-Dong; Wang, Yong-Sheng; Wang, Jun-Ye; Liang, Xiao-Hua; Wu, Xiao-Jie; Zheng, Yu-Long; Liu, Jian; Shi, Xi; Liu, Wei; Chen, BoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2023-11 To 2023-11.
会议论文
A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.
1被引7阅读
